CLINICAL STUDY ON TE-031 (A-56268) AGAINST MALE URETHRITIS

• Published in: CHEMOTHERAPY Vol. 36; no. Supplement3; pp. 827 - 831
• Main Authors: MURANAKA, KOJI, ISOMATSU, YUKISHIGE, KAWADA, YUKIMICHI, SHIMAZU, RYOICHI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1988
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.36.Supplement3_827

We examined the clinical effect and safety of TE-031 (A-56268) in male urethritis. The subjects were 3 patients with gonococcal, 3 with chlamydial and 4 with non-gonococcal non-chlamydial urethritis. TE-031 was given at a daily dose of 300-800 mg for 3-14 days, after which we examined the patients for gonococci and chlamydiae, and assessed clinical progress. Gonococci and chlamydiae were eradicated in all cases after administration of TE-031. As to global clinical effect, TE-031 was markedly effective in 2 and slightly effective in 1 of 3 cases of gonococcal urethritis. In 3 cases of chlamydial urethritis, the drug was markedly effective, effective and slightly effective in 1 case each, and in 4 cases of non-gonococcal non-chlamydial urethritis, markedly effective in all cases. As to side-effects, rash was observed in the lower extremities of one patient on the second day of administration, but blood biochemistry was normal in all cases.